GSK’s Stiefel Adds Psoriasis/Atopical Dermatitis Candidate In Licensing Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
For about $34 million, Stiefel gets development and commercialization rights in most of the world to a novel, non-steroidal, topical anti-inflammatory compound in Phase II.